Bispecific Macrophage Nano-Engager Couples Dual Checkpoint Blockade with Stimulator of Interferon Genes Activation to Potentiate Antitumor Immunity

  • Dang, Bao-Toan; 
  • Pham, Khang-Yen; 
  • Le, Huyen Thi Thu; 
  • Nguyen, Thoa Thi Kim; 
  • Vu, An Thi Thanh; 
  • 외 5명
Citations

WEB OF SCIENCE

2

초록

The immunosuppressive tumor microenvironment, characterized by impaired antigen presentation, "don't eat me" signaling, and T-cell exhaustion, challenges effective cancer immunotherapy. Conventional T-cell-redirecting bispecific engagers (BiTEs) show limited efficacy in solid tumors because of poor T-cell infiltration, rapid clearance, and dose-limiting cytokine release associated with the CD3 agonism. Therefore, we aimed to enhance macrophage-mediated tumor clearance and T-cell priming by developing a bispecific macrophage nanoengager (nanoBIME) that integrates dual immune checkpoint blockade (anti-SIRP alpha and anti-PD-L1) with STING-agonist delivery (SR717) in a single poly(lactic-co-glycolic acid) nanocarrier (BIS-PLGA-NP@SR717). BIS-PLGA-NP@SR717 exhibited uniform nanoscale features, efficient SR717 encapsulation, and stable dual-antibody conjugation, enabling systemic delivery with sustained intracellular release. Dual-ligand presentation markedly enhanced receptor binding and nanoparticle uptake in macrophages and PD-L1-expressing tumor cells. BIS-PLGA-NP@SR717 synergistically promoted macrophage phagocytosis, repolarized tumor-associated macrophages toward an M1 phenotype, enhanced dendritic cell maturation, and CD8(+) T-cell activation; additionally, it elevated granzyme B, perforin, and IFN-gamma production, resulting in robust T-cell-dependent tumor cell killing. In CT26 tumor-bearing mice, BIS-PLGA-NP@SR717 achieved superior tumor accumulation, deep intratumoral penetration, and dose-dependent tumor regression with minimal systemic toxicity. Transcriptomic profiling further revealed the coordinated activation of phagosome-related pathways, antigen presentation, STING/IFN pathways, chemokine signaling, and T-cell receptor engagement. Collectively, BIS-PLGA-NP@SR717 represents an integrated, multiaxis immunotherapeutic nanoplatform that synchronizes innate activation, macrophage remodeling, and T-cell effector functions. Its modular architecture provides a versatile framework for next-generation immunotherapies for solid tumors.

키워드

nanoparticles; bispecific macrophage nanoengager; macrophage phagocytosis; signal regulatory protein; programmed death-ligand 1; STING agonist; cancerimmunotherapy; STING ACTIVATION; CANCER; NANOPARTICLES; CD47
제목
Bispecific Macrophage Nano-Engager Couples Dual Checkpoint Blockade with Stimulator of Interferon Genes Activation to Potentiate Antitumor Immunity
저자
Dang, Bao-Toan; Pham, Khang-Yen; Le, Huyen Thi Thu; Nguyen, Thoa Thi Kim; Vu, An Thi Thanh; Giri, Anil; Shrestha, Prabhat; Kwon, Taeg Kyu; Jeong, Jee-Heon; Yook, Simmyung
DOI
10.1021/acsnano.6c01144
발행일
2026-06
유형
Article
저널명
ACS Nano
권
20
호
21
페이지
15230 ~ 15252